Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | CLK3 | P49761 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26685843 | 1.00 | TBK1 (0.55) | TBK1HRH4HRH3JAK2MAP3K11 | |
| SCHEMBL31420127 | 0.91 | TBK1 (0.53) | TBK1HRH4HRH3JAK2CLK2 | |
| SCHEMBL26685751 | 0.91 | TBK1 (0.53) | TBK1HRH4HRH3JAK2CLK2 | |
| SCHEMBL31240414 | 0.84 | CCNT1 (0.49) | JAK2MAP3K11CLK2CLK3DYRK1A | |
| SCHEMBL26685791 | 0.82 | NUDT1 (0.60) | JAK2CLK2CLK3DYRK1A | |
| SCHEMBL26686408 | 0.82 | NUDT1 (0.48) | JAK2CLK2CLK3DYRK1A | |
| SCHEMBL31240425 | 0.82 | NUDT1 (0.48) | JAK2CLK2CLK3DYRK1A | |
| SCHEMBL31420159 | 0.82 | NUDT1 (0.60) | JAK2CLK2CLK3DYRK1A | |
| SCHEMBL30633398 | 0.81 | NUDT1 (0.46) | JAK2CLK2CLK3DYRK1A | |
| SCHEMBL26686152 | 0.81 | NUDT1 (0.46) | JAK2CLK2CLK3DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705291-A1 | IKK-ALPHA INHIBITORS | Cancer Research Technology Limited (GB) | 2026-03-11 | — | — | EP | claimed |
| CN-119562945-A | IKK inhibitors | 癌症研究技术有限公司 | 2025-03-04 | — | — | CN | claimed |
| WO-2024228035-A1 | IKK-ALPHA INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-11-07 | — | — | WO | claimed |
| EP-4705291-A1 | IKK-ALPHA INHIBITORS | Cancer Research Technology Limited (GB) | 2026-03-11 | — | — | EP | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119562945-A | IKK inhibitors | 癌症研究技术有限公司 | 2025-03-04 | — | — | CN | disclosed |
| WO-2024228035-A1 | IKK-ALPHA INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-11-07 | — | — | WO | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |